Selecta Biosciences, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SELB research report →
About the company
Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical firm dedicated to the research and development of innovative nanoparticle immunomodulatory medications aimed at treating and preventing various human ailments. The company's most advanced gene therapy initiative is SEL-302, currently in preclinical development to enhance therapeutic options for methylmalonic acidemia.
- CEO
- Carsten Brunn
- IPO
- 2016
- Employees
- 64
- HQ
- Watertown, MA, US
Price Chart
- Market Cap
- $135.20M
- P/E
- -0.15
- P/S
- 76.17
- P/B
- -0.16
- EV/EBITDA
- -1.61
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- -8550.65%
- ROE
- 194.13%
- ROIC
- 0.00%
- Revenue
- $2.80M · -92.81%
- Net Income
- $-130,302,000 · -68.30%
- EPS
- $-5.02 · -904.00%
- Op Income
- $0
- FCF YoY
- -142.30%
- 52W High
- $1.99
- 52W Low
- $0.79
- 50D MA
- $1.10
- 200D MA
- $1.19
- Beta
- 0.83
- Avg Volume
- 634.42K
Get TickerSpark's AI analysis on SELB
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 2, 24 | Singer Michael | other | 178,000 |
| Jan 2, 24 | Singer Michael | other | 228,000 |
| Dec 22, 23 | Singer Michael | other | 3,000 |
| Jan 2, 24 | Davis Blaine | other | 3,110,000 |
| Jan 2, 24 | Davis Blaine | other | 2,424,000 |
| Jan 2, 24 | Jewell Christopher M | other | 998,000 |
| Jan 2, 24 | Jewell Christopher M | other | 778,200 |
| Jan 2, 24 | Brunn Carsten | other | 5,971,000 |
| Jan 2, 24 | Brunn Carsten | other | 4,654,100 |
| Jan 2, 24 | Sallin Aymeric | other | 228,000 |
Our SELB coverage
Recent articles, reports, and earnings notes.
No research on SELB yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SELB report →Similar companies
Peers in the same neighborhood.